-
Posted by
Two Blokes Jul 2 -
Filed in
Stock
-
6 views
Centene's stock plunged after slashing 2025 EPS guidance due to higher-than-expected morbidity and lower market growth in key states. The company's previous bullish guidance failed to materialize. Despite the sharp drop, Centene trades at historically low price-to-sales multiples and investment grade status, making valuation attractive for risk-tolerant investors.
